logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pembrolizumab inaddition to chemotherapy for persistent, recurrent or metastatic cervical cancer – first line

< Back

Pembrolizumab inaddition to chemotherapy for persistent, recurrent or metastatic cervical cancer – first line

Drugs

Cancer and Palliative Care

April 2020


Pembrolizumab, in addition to chemotherapy, is being developed for the treatment of persistent, recurrent or metastatic cervical cancer. Cervical cancer develops in the lower part of the womb and mainly affects sexually active women aged between 30 and 45 years. Cervical cancer that has spread to another part of the body is called advanced or metastatic cancer. Cancer that returns after months or years of the completion of the initial treatment is called recurrent cancer. Whilst chemoradiotherapy (chemotherapy and radiotherapy) is offered to patients with cervical cancer, women with recurrent or metastatic cervical cancer represent a poor prognostic group with high, unmet clinical needs.

Pembrolizumab is an immunomodulatory medicinal product, meaning that it helps the immune system to recognise and attack cancer cells. It is administered by intravenous infusion and is currently licensed in the UK for melanoma, non-small cell lung cancer and urothelial cancer – amongst others. If licensed, pembrolizumab, in addition to chemotherapy, would offer an alternative treatment for those with advanced, recurrent or metastatic cervical cancer.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts